No Dedicated Drugs for Alzheimer’s Disease Psychosis; Acadia Candidate Receives FDA Fast Track Designation
Remlifanserin targets hallucinations and delusions, with Phase 2 results expected this fall and Phase 3 enrollment already launched ahead of schedule; as the regulatory process accelerates, evidence of efficacy and safety still awaits answers from publicly available data.